Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

22.10.2018 | review | Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018

Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse

memo - Magazine of European Medical Oncology > Ausgabe 4/2018
Ali Amin Asnafi, Niloofar Farshchi, Abbas Khosravi, Neda Ketabchi, Masumeh Maleki Behzad, Ph.D Saeid Shahrabi
Wichtige Hinweise

Authors’ contributions

S. Shahrabi conceived the manuscript and revised it. A.A. Asnafi, N. Farshchi, A. Khosravi, N. Ketabchi, and M.M. Behzad wrote the manuscript and prepared the tables.



Leukemia is one of the most important hematological malignancies. Despite progress in leukemia therapy, recurrence is still one of the main reasons for treatment failure. Recently, gene polymorphisms have been the focus of attention as important factors in the recurrence of leukemia.


Relevant literature was identified by an electronic database search (1996–2018) of English-language literature using the terms “polymorphism”, “leukemia”, “prognosis”, “lymphoma”, and “relapse.”


Polymorphisms of genes involved in cell cycle, apoptosis, immune system, and drug metabolism enzymes have been associated with progression of hematological malignancies. These genetic changes can be associated with relapse and unfavorable clinical outcomes through potential impact on leukemic cells survival.


Considering the fact that gene polymorphisms could significantly affect pathophysiology of hematological malignancies, these genetic changes may be considered as potential prognostic biomarkers and therapeutic agents in these disorders.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018 Zur Ausgabe